Sanofi US News

Sanofi to lower out-of-pocket cost of insulin for uninsured patients and expand access in underserved communities
Through the Insulins Valyou Savings Program, uninsured people living with diabetes will pay fixed $35 for a 30-day supply of Sanofi insulins
Sanofi US announces new collaboration with Direct Relief to help provide free insulin to reach more underserved communities

BRIDGEWATER, NJ, June 29, 2022– Effective July 1, uninsured people living with diabetes in the United States will be able to obtain one or multiple Sanofi insulins* from our Insulins Valyou Savings Program with a valid prescription for a total of $35 for a 30-day supply. Previously, the program offered a 30-day supply of Sanofi insulins for $99.

Adam Gluck

Head of U.S. and Global Specialty Care Corporate Affairs, Sanofi

“Informed by patient feedback, Sanofi has updated our industry-leading assistance program to continue addressing access and affordability challenges for all people living with diabetes, regardless of insurance coverage. This is yet another example of our determination to partner with the patient community and meet our commitment to ensure every patient can access and afford the insulin they need.    

Sanofi believes that people living with diabetes should not face high out-of-pocket costs at the pharmacy counter. Individuals can access the program regardless of income level. In 2021, the Insulins Valyou Savings Program was used more than 97,000 times and provided more than $37 million in savings to people living with diabetes.

For more information or to learn how to access this program, visit

Working to advance health equity for people living with diabetes

Sanofi is also announcing a new collaboration with Direct Relief to tackle the unique challenges faced by people living with diabetes in some underserved communities. Often, these individuals will require another appointment or pharmacy visit to receive their medication which demands added time off work and the use of public transportation. Additionally, they may need initial support from a healthcare professional to properly use the medication.  To address these barriers and improve patient access, Sanofi Cares North America will donate the company’s insulin and combination diabetes medicines to Direct Relief, at no cost, to ensure eligible safety net health facilities have medication on hand when a patient is diagnosed and prescribed.

We believe this collaboration, which aims to provide vital Sanofi medication to thousands of people living with diabetes in its first year, will help to bridge the care gap between diagnosis and treatment, drive medication compliance and help to improve health outcomes. This collaboration comes in addition to Sanofi’s existing work to assist Direct Relief in responding to disasters.

For more information or to learn how to access this program, contact

Additional resources available for acces­sing and affording Sanofi diabetes medicines

Sanofi continues to offer other patient-centric savings programs to make insulins accessible and affordable. All commercially insured people are eligible for our co-pay assistance programs, regardless of income or insurance plan design, which limits out-of-pocket expenses for a majority of people between $0 and $10. Sanofi also provides free medications to qualified low- and middle-income patients through the patient assistance component of the Sanofi Patient Connection program. Sanofi is also a part of the Centers for Medicare and Medicaid Services’ (CMS) Senior Savings Model, which allows patients enrolled in participating Part D plans to pay a $35 or less co-pay for each 30-day prescription of a Sanofi insulin throughout the year.

­­­Sanofi also recently launched Insulin Glargine Injection U-100 (100 units/mL) at a price that is 60% less than the current Lantus® (insulin glargine injection) 100 Units/mL list price. Sanofi understands that certain payers want to have different Insulin Glargine U-100 options, so Sanofi will continue to offer Lantus to payers who choose to cover the existing product.  The availability of Insulin Glargine Injection U-100 in local markets will depend on payer coverage, pharmacy purchasing patterns and wholesaler stocking decisions.

Collectively, these savings offerings demonstrate the company's commitment to providing support to help all patients gain access to the Sanofi medicines they need.

Every patient has unique financial circumstances, and Sanofi has live support specialists who can be reached at (855) 984-6302 to answer individual patients’ questions and navigate their personal situations to find the best resources and programs to help lower their out-of-pocket costs.

* The Insulins Valyou Savings Program does not include Sanofi’s combination insulin product.

What is Lantus® and Insulin Glargine U-100?

Prescription Lantus and Insulin Glargine U-100 are long-acting insulins used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar.

  • Do not use Lantus or Insulin Glargine U-100 to treat diabetic ketoacidosis.

Important Safety Information for Lantus® and Insulin Glargine U-100

The Important Safety Information for Insulin Glargine U-100 is the same as for Lantus.

Do not take Lantus during episodes of low blood sugar or if you are allergic to insulin or any of the inactive ingredients in Lantus.

Do not share needles, insulin pens, or syringes with others. Do NOT reuse needles.

Before starting Lantus, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breast-feeding or planning to breast-feed.

Change (rotate) your injection sites within the area you chose with each dose to reduce your risk of getting pitted or thickened skin (lipodystrophy) and skin with lumps (localized cutaneous amyloidosis) at the injection sites. Do not use the same spot for each injection or inject where the skin is pitted, thickened, lumpy, tender, bruised, scaly, hard, scarred or damaged.

Heart failure can occur if you are taking insulin together with certain medicines called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you already have heart failure, it may get worse while you take TZDs with Lantus. Your treatment with TZDs and Lantus may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms of heart failure, including:

  • Shortness of breath
  • Swelling of your ankles or feet
  • Sudden weight gain

Tell your doctor about all the medications you take, including over the counter medicines, vitamins, and supplements, including herbal supplements.

Lantus should be taken once a day at the same time every day. Test your blood sugar levels while using insulin, such as Lantus. Do not make any changes to your dose or type of insulin without talking to your healthcare provider. Any change of insulin should be made cautiously and only under medical supervision.

Do NOT dilute or mix Lantus with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Lantus must only be used if the solution is clear and colorless with no particles visible. Always make sure you have the correct insulin before each injection. While using Lantus, do not drive or operate heavy machinery until you know how Lantus affects you. You should not drink alcohol or use other medicines that contain alcohol.

The most common side effect of insulin, including Lantus, is low blood sugar (hypoglycemia), which may be serious and life threatening. It may cause harm to your heart or brain. Symptoms of serious low blood sugar may include shaking, sweating, fast heartbeat, and blurred vision. Lantus may cause serious side effects that can lead to death, such as severe allergic reactions. Get medical help right away if you have:

  • A rash over your whole body
  • Trouble breathing
  • A fast heartbeat
  • Sweating
  • Swelling of your face, tongue, or throat
  • Shortness of breath
  • Extreme drowsiness, dizziness, or confusion

Other possible side effects may include swelling, weight gain, low potassium levels, injection site reactions, including changes in fat tissue at the injection site, and allergic reactions.

Important Safety Information for Lantus® (insulin glargine injection) SoloStar® and Insulin Glargine U-100 SoloSTAR®

Lantus SoloSTAR and Insulin Glargine U-100 SoloSTAR are disposable single-patient-use prefilled insulin pens. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instruction Leaflet that accompanies the pen.

Click here for Full Prescribing Information for Lantus.

Click here for Full Prescribing Information for Insulin Glargine U-100.

Click here for information on Sharps Medical Waste Disposal.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs


About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY


Media Relations

Evan Berland | + 1 215 432 0234 |

Sally Bain | + 1 617 834 6026 |


Investor Relations

Eva Schaefer-Jansen | + 33 7 86 80 56 39 |  

Arnaud Delépine | + 33 6 73 69 36 93 |  

Corentine Driancourt | + 33 6 40 56 92 21 |   

Felix Lauscher | + 1 908 612 7239 |

Priya Nanduri | +1 617 764 6418 |    

Nathalie Pham | + 33 7 85 93 30 17 | 


Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2021. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.